This site is intended for healthcare professionals only
DiabetesontheNet Logo

Diabetes Digest


Early View

Share this article

Switching from flash to CGM reduces hypoglycaemia risk

Devices – April 2019 digest

Extension of the I HART CGM Study looking at the impact of switching from flash monitoring to continuous glucose monitoring.

Reddy M, Jugnee N, Anantharaja S, Oliver N (2018) Switching from Flash Glucose Monitoring to Continuous Glucose Monitoring on Hypoglycemia in Adults with Type 1 Diabetes at High Hypoglycemia Risk: The Extension Phase of the I HART CGM Study. Diabetes Technol Ther 20: 751–7 

  • Recurrent hypoglycaemia can impair awareness of its associated symptoms and lead to severe hypoglycaemia, resulting in increased morbidity and mortality.
  • This paper reports on a continuation of the I HART CGM Study, which demonstrated that real-time continuous glucose monitoring (RT-CGM) reduced the risk of hypoglycaemia in high-risk adults with type 1 diabetes compared to flash glucose monitoring.
  • In this blinded extension study, 40 participants with impaired hypoglycaemia awareness or a recent episode of severe hypoglycaemia were randomised to flash or RT-CGM for 8 weeks and then given the opportunity to start or continue to use RT-CGM for a further 8 weeks. 
  • Thirty-six participants completed the 16-week extension. Investigators compared participants’ glycaemic outcomes at 8 and 16 weeks.
  • In the group that switched from flash to RT-CGM, the percentage of time spent in hypoglycaemia dropped significantly from 5% to 0.8% (P=0.0001). Time spent in hypoglycaemia in the group continuing to use RT-CGM was the same at 8 and 16 weeks (1.3% versus1.3%).
  • The proportion of time spent within the target glycaemic range (21–63 mmol/mol; 4.1–7.9%) remained the same in the group that continued using RT-CGM but increased in the group switching from flash monitoring.
  • Investigators concluded that changing from flash to RT-CGM results in significant improvements in hypoglycaemia outcomes and that the benefit of RT-CGM use is maintained over time in high-risk patients with type 1 diabetes. 

Click here to access the article in full

Related content
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals


By clicking ‘Subscribe’, you are agreeing that are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.